cardiologist, trialist, researcher, professor, medical director cardiology Heart Center Leipzig at University of Leipzig, President German Cardiac Society
Last day
@PhilippLurz
after 21 years at Heart Center Leipzig. Now heading to become chief of cardiology at
@uni_mainz
. All the best for the start and great success!
@KP_Kresoja
Congrats to Danger team
@CHassager
! Impressive results, now after SHOCK and Culprit-Shock 3rd positive RCT. Nevertheless, multiple questions remain: 1) is it the device? 2) patient selection? 3) treatment bias? 4) longer follow-up?
@seanvandiepen
@JBauersachsMD
@NavinKapur4
First MitraClip generation 4 in Europe just finished at Heart Center Leipzig! Perfect result with XT-W. Thank you to the team!
@AGIKinterv
@PhilippLurz
Consistent data from propensity matched studies. More complications with Impella, no mortality benefit.
See Dhruva et al. JAMA 2020 and Amin et al. Circulation 2020 and Schrage et al. Circulation 2019. We urgently need RCTs!
#DanGer
#ECLS
-SHOCK
Impella vs. IABP in
@JAMAInternalMed
- Propensity-matched analysis
- 817 patients with AMI-CS undergoing PCI
- Impella associated with higher 30d/1yr mortality, more bleeding and RRT and higher costs
#Impella
#IABP
💥 breaking news 💥
Aktuell auf dem
#ESCCongress
von
@thiele_holger
vorgestellt und im
@lancet
veröffentlicht:
Die ECLS-SHOCK-Studie:
▶️ KEIN Vorteil für VA-ECMO im infarktbedingten kardiogenen Schock 💥
Nun gilt es zu analysieren, wer von der Therapie ggf. doch profitiert.
Here the key messages on mechanical support in cardiogenic shock. RCTs: more complications, no signal on mortality reduction. Matched comparisons: more complications, higher mortality. We need RCTs!
@seanvandiepen
@Borjaibanez1
@alaide_chief
We are happy to share our latest contribution to Circulation: Scrutinizing the Role of Venoarterial Extracorporeal Membrane Oxygenation: Has Clinical Practice Outpaced the Evidence? | Circulation
@CircAHA
@thiele_holger
@LBinzenhofer
@cardio_lmu
Interesting discussions. Some criticize that patients were too sick and others that patients were with SCAI C not sick enough for VA-ECMO. Is 50% mortality not clear that this were advanced shock patients? SCAI is nice but it is a dynamic and also partly subjective grading
Great study by
@thiele_holger
. Using VA ECMO as a go-to for shock doesn’t improve outcomes. Half of patients were SCAI stage C.Most high-quality centers don’t use ECMO for stage C shock. If you use ECMO early & often, you’re using it wrong. But the best way is still not known.
I like the trial and the results. However, a treatment bias with more intensive care treatment as shown by the non-pathophysiological explainable RRT increase may also be a confounder of the trial results.
Welcome to the ECLS-SHOCK party!
Now only 120 patients to go.
Hopefully by end of year 2022 finalized. ECLS-SHOCK will define if ECMO improves survival in
@SCAI
shock D + E stages
@NavinKapur4
@AGIKinterv
@dzhk_germany
summary slide of evidence for mechanical circulatory support. RCTs limited to 201 patients so far with no mortality reduction.5 matched comparisons all showing more complications and 4 higher mortality!!!
@susannaprice
@alaide_chief
@mmamas1973
@seanvandiepen
Honestly, I do not understand why people still believe in IABP. Is it because we want to help our patients with 50% mortality rate but do not have anything which has proven to work?
@drtrc99
Several randomized trials available and 66% of questionned people say yes...IABP doesn't have any role for CS (and probably for AMI related complications).
@thiele_holger
Not sure if I am Mr. Negative trial. CULPRIT-SHOCK was clearly positive. And neutral or negative trials reflect also scientific valid and usually well-conducted trials.
Very very sad news. I had the chance to work with him over years in particular for
@escardio
NSTE-ACS guidelines 2020. I am shocked to have lost a friend
Very sad news today as my friend and great expert Pr Jean Philippe Collet let us suddenly. Great cardiologist and researcher, very kind with patients and team. I ´d rather keep him smiling. No words.
A shout out to
@thiele_holger
& colleagues for carrying out CULPRIT-SHOCK - they didn’t contend with the status quo & their work will meaningfully impact lives of patients.
1st study:
1-year outcomes:
What are the most impactful trials presented at
#ESCCongress
and why?
ECLS Shock showing ECMO does not improve survival in CS shock?
ILUMIEN 4 showing no improvement in outcomes 2 yrs later with OCT over angio?
Stop DAPT 3 showing we still need 1 month of DAPT?
Recipients - Highly Cited | Researcher Recognition
I am proud and privileged to be for first time among the 6200 highly cited researchers in 2020
@Steph_Achenbach
@DLBHATTMD
In Germany 16 cardiologists awarded